{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:33:41Z","timestamp":1772930021247,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41409-021-01434-3","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:02:58Z","timestamp":1628593378000},"page":"2626-2627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"56","author":[{"given":"Iman","family":"Abou Dalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1158\/1078-0432.ccr-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26:6475\u201382. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-3134. e-pub ahead of print 2020\/09\/30","journal-title":"Clin Cancer Res"},{"key":"1434_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","volume":"119","author":"C Schmid","year":"2012","unstructured":"Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599\u2013606. https:\/\/doi.org\/10.1182\/blood-2011-08-375840. e-pub ahead of print 2011\/12\/15","journal-title":"Blood"},{"key":"1434_CR3","doi-asserted-by":"publisher","unstructured":"Zucenka AVV, Maneikis K, Davainis L, Pileckyte R, Trociukas I, et al. Venetoclax based salvage therapy followed by venetoclax and DLI maintenance vs FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021. https:\/\/doi.org\/10.1038\/s41409-021-01416-5. Epub ahead of print.","DOI":"10.1038\/s41409-021-01416-5"},{"key":"1434_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971. e-pub ahead of print 2020\/08\/14","journal-title":"N Engl J Med"},{"key":"1434_CR5","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345. https:\/\/doi.org\/10.1182\/blood.2020004856. e-pub ahead of print 2020\/03\/29","journal-title":"Blood"},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401\u20137. https:\/\/doi.org\/10.1002\/ajh.25000. e-pub ahead of print 2017\/12\/09","journal-title":"Am J Hematol"},{"key":"1434_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00437-z","volume":"11","author":"M Joshi","year":"2021","unstructured":"Joshi M, Cook J, McCullough K, Nanaa A, Gangat N, Foran JM, et al. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J. 2021;11:49. https:\/\/doi.org\/10.1038\/s41408-021-00437-z. e-pub ahead of print 2021\/03\/06","journal-title":"Blood Cancer J"},{"issue":"9","key":"1434_CR8","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404\u2013e407. https:\/\/doi.org\/10.3324\/haematol.2018.188094. e-pub ahead of print 2018\/03\/17","journal-title":"Haematologica"},{"key":"1434_CR9","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, et al. Venetoclax combined With FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021: Jco2003736. e-pub ahead of print 2021\/05\/28; https:\/\/doi.org\/10.1200\/jco.20.03736","DOI":"10.1200\/jco.20.03736"},{"key":"1434_CR10","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.cd-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566\u201381. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0140. e-pub ahead of print 2018\/09\/07","journal-title":"Cancer Discov"},{"key":"1434_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/blood-2019-123711","volume":"134","author":"NG Daver","year":"2019","unstructured":"Daver NG, Garcia JS, Jonas BA, Kelly KR, Assouline S, Brandwein JM, et al. Updated results from the venetoclax (Ven) in combination with idasanutlin (Idasa) arm of a phase 1b trial in elderly patients (Pts) with relapsed or refractory (R\/R) AML ineligible for cytotoxic chemotherapy. Blood. 2019;134:229. https:\/\/doi.org\/10.1182\/blood-2019-123711","journal-title":"Blood"},{"key":"1434_CR12","doi-asserted-by":"publisher","unstructured":"Wu HC, R\u00e9rolle D, Berthier C, Hleihel R, Sakamoto T, Quentin S, et al. Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy. Cancer Discov. 2021:candisc.0177.2021. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0177. Epub ahead of print","DOI":"10.1158\/2159-8290.CD-21-0177"},{"key":"1434_CR13","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, Labopin M, Battipaglia G, Djabali A, Forcade E, Arcese W, et al. Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. A retrospective acute leukemia working party\u2014European Society for Blood and Marrow Transplant Study. Clin Hematol Int. 2019-03-17T23:00:00.000Z; 1: 58\u201374.","DOI":"10.2991\/chi.d.190310.001"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01434-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T20:21:07Z","timestamp":1655238067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01434-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01434-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"17 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}